Vaccinogen Announces Establishment of a Distribution Relationship with Deutsches Grunes Kreuz ("DGK") for Distribution of OncoVAX® in Germany
- October 22, 2009
- Vaccinogen Announces New Relationship with CRO Clinipace Worldwide
- July 24, 2009
- Vaccinogen Announces Submission of Final Documentation to Swissmedic for Pivotal Review of OncoVAX®
- April 20, 2009
- Vaccinogen Announces That Michael G. Hanna, Jr., Ph.D. is Scheduled to Speak at the Barcelona Vaccine Forum 2009 in June 2009
- February 11, 2008
- Cancer Pioneer Reaches Key Agreement On Colon Cancer Drug OncoVAX®
- November 3, 2007
- Vaccinogen Announces Completion of its Initial Capitalization Plan
- October 1, 2007
- Vaccinogen Announces Formation of Company
- July 19, 2006
- FDA Grants Special Protocol Assessment
Frederick, MD, USA – May 15, 2009 – Vaccinogen, Inc. announces a new distribution partnership with DGK whereby DGK will handle the marketing and distribution activities of OncoVAX ® throughout Germany.
"We are fortunate to have DGK as our partner for Germany," said Michael G. Hanna, Jr., Ph.D., Chairman & CEO of Vaccinogen. "Germany has the fourth highest number of colon cancer cases per year in the world. It is important to properly approach these patients with the highest caliber partner, which is what we have with Dr. von Stackelberg and his team."
Dr. Hans von Stackelberg noted, "We are excited at this excellent opportunity to bring forth OncoVAX ® to the 15,000+ Germans who are diagnosed with Stage II colon cancer each year."
About DGK
Led by Dr. Hans von Stackelberg, DGK is a 60 year-old multifaceted organization that has been the standard for medical information and advice in Germany. Headquartered in Marburg, Germany, it has 75 medical professionals.
About OncoVAX®
OncoVAX® immunotherapy is based on a decades-long attempt by scientists to transform the body’s immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.
Vaccinogen’s scientists prepare a vaccine from the patient’s own tumor and then administer the vaccine to the patient by three weekly injections one month after surgery. A fourth “booster” is administered six months later. OncoVAX® reduces recurrence and deaths by over 50%.
About Vaccinogen
Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, antiinflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The Company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for producing OncoVAX® vaccines.
Vaccinogen’s online press kit: http://www.vaccinogeninc.com/
Andrew L. Tussing
Vaccinogen
atussing@vaccinogeninc.com
301-668-8400